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Abstract
Background: There is evidence suggesting that the pregnancy outcome may be
affected by some medical conditions, such as liver diseases.
Objective: The present study aimed to investigate the prevalence of liver disease and
its outcomes in pregnant women referred to antenatal clinic in the hospital.
Materials and Methods: In this cross-sectional study, all pregnant women with
abnormal liver function test attending antenatal clinic affiliated to Shahid Beheshti
University of Medical Sciences were recruited from August 2017 to July 2018. All
participants were followed-up until delivery with respect to the maternal and neonatal
outcome.
Results: Of a total of 7,121 pregnant women recruited in the study, 110 (1.58%) women
were detected with a liver disease; of these, 105 women were diagnosed with
pregnancy-specific liver diseases, including HELLP syndrome (10.9%), preeclampsia
(50.98%), partial HELLP (0.9%), eclampsia (0.9%), acute fatty liver (9.1%), intra-hepatic
cholestasis 25 (22.7%), and 5 women the non-pregnancy-specific liver disease,
including Liver transplantation (2.7%), and Autoimmune hepatitis (1.8%). Prevalence of
the premature birth was 64.5% in pregnancy-specific liver disease, but no premature
birth was detected in cases with liver transplantation. We found that neonatal mortality
was significantly associated with neonatal prematurity (p = 0.013), IUGR (p < 0.001),
placental pathology (p = 0.04), we had no maternal mortality.
Conclusion: Liver disease is not uncommon in pregnancy. This study demonstrated
that pregnancy is safe in women with liver disease.
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1. Introduction
About 3-5% of pregnancies are complicated by
an abnormal liver function test, which can affect
pregnancy outcomes depending on the severity
of the disease. Several factors may be resulted in
abnormal liver enzyme tests in pregnant women,
including physiological changes in pregnancy,
acquired the liver disease during pregnancy, pre-
existing liver disease, and pregnancy-related liver
disease. Interestingly, an abnormal liver function
test, which results due to the physiologic changes
and occurs in pregnant women without liver
dysfunction, had a unique pattern and can be
recognized when compared with the normal range
of liver function test (1).
Preeclampsia is considered as themost common
cause of liver dysfunction in pregnancy. Some
cases are further complicated by HELLP, partial
HELLP syndrome [H (hemolysis), EL (elevated liver
enzymes), LP (low platelet count)], and eclampsia.
Delivery is the only definitive therapy in such
conditions, since many maternal complications
may occur, including placental abruption, renal
failure, subcapsular hematomas, and hepatic
rupture (2-6). Cholestasis of pregnancy, which
is typically presented by generalized pruritus,
predominately on the palms of the hands and the
soles of the feet, and the condition is worse at
night, may be associated with liver dysfunction
(7-14). Acute fatty liver of pregnancy is a sudden
fatal disorder occurring almost exclusively in
the third trimester of pregnancy; fatty infiltration
of hepatocytes causes acute hepatic failure
with coagulopathy and encephalopathy. Due to
this fatal liver dyfunction, early diagnosis and
immediate delivery is essential for maternal
and fetal survival (15). Also, liver transplantation
is considered to be the choice treatment for
end-stage liver disease and its success has led
to an increase in the number of female liver
transplantation. While reproductive ages women
with autoimmune hepatitis may become pregnant,
the pregnancy outcome has not well clarified in
such women. On the other hand, the complications
of liver disease in pregnancy can affect the
maternal and neonatal health, although there
is no comprehensive study investigating these
outcomes in Iranian pregnant women. Therefore,
this study aimed to investigate the prevalence of
liver disease and evaluate pregnancy outcomes
in these patients in the population of pregnant
women referred to prenatal clinics affiliated to
Shahid Beheshti University of Medical Sciences
(SBMU), Tehran, Iran.
2. Materials and Methods
In this cross-sectional study, of 7121 pregnant
women attending to anetatal clinic affiliated to
SBMU assessed for eligibility critera, the number
of 110 pregnant women with various types of
liver disease were recruited from August 2017 to
July 2018. Our inclusion criteria were all pregnant
women with liver disorders during pregnancy,
thosewith previous hepatic disorders and/ or those
with previous liver transplantation. Women with
drug induced abnormal liver function test were
excluded from the study.
The diagnosis of liver disease was made
based on the symptom and sign and liver
function tests including SGOT, SGPT, Bilirubin
were studied along with some more definitive
tests such as CBC, Plasma glucose, Urinary
protein, Urea, Creatinine, LDH, Peripheral smear
to aid identification of underlying cause. Study
participants were admitted in the obstetric ward.
After obtaining the demographic, menstrual and
obstetric histories, the specific symptoms related
to liver dysfunction such as pruritus, persistant
vomiting, blurring of vision, diminished urine
output,upper abdominal pain and anorexia were
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asked, and then a thorough general and obstetric
examination were carried out for all participants.
During hospitalization, all clinical manifestation
were observed and laboratory test was checked
two times per week. Any deterioration in clinical
manifestation, such as severe hypertension, severe
headache, epigastric pain, or change in laboratory
test, such as increasing liver enzymes or creatinine,
termination of pregnancy was done. Patients were
followed up till two weeks postpartum.
HELLP syndrome was diagnosed based on
the following criteria: complete: raised bilirubin,
elevated AST (> 70 IU/L), low platelet count
(< 100,000/μL), hemolysis (suggestive peripheral
smear with schiztocyte along with increased
reticulocytes). Partial: elevated AST (> 40 IU/L),
low platelet count (< 150,000/μL), the absence or
presence of hemolysis.Pre-eclampsia-associated
liver dysfunction was diagnosed based on the
elevated transaminases or bilirubin in the presence
of hypertension to the extent of 140/90 mmHg or
more on two occasions > 6 h apart, proteinuria
(1+) after 20 weeks of pregnancy.Intrahepatic
cholestasis of pregnancy (ICP) was detected
based on having pruritus without any skin
problem or allergy with elevated transaminases.
Relieved after delivery. Acute Fatty Liver of
Pregnancy (AFLP) was diagnosed with having six
or more signs, including-vomiting, abdominal pain,
encephalopathy, leucocytosis, elevated bilirubin,
elevated transaminases, marked hypoglycaemia,
renal impairment, coagulopathy.Autoimmune
hepatitis was diagnosed for patients with chronic
hepatitis, and increased liver enzymes.
All maternal information, including liver enzyme
reversibility to the normal range, mode of delivery,
maternal age, gestational age, and neonatal
information, including Apgar score, birth weight,
prematurity, intrauterine growth restriction (IUGR),
and neonatal mortality were extracted from the
postpartum records of the participants.
2.1. Ethical consideration
This study was approved by the ethics
committee of the Shahid Beheshti University
of Medical Sciences (IR.SBMU.MSP.REC.1398.917)
and informed consent was obtained from all
participants.
2.2. Statistical analysis
Data were analyzed using the SPSS software
version 21 (Statistical Package for the Social
Sciences,version 21.0, SPSS Inc, Chicago, Illinois,
USA). The Chi-square Fisher and U-Mann-Whitney
tests were used to compare the study parameters.
P < 0.05 was considered significant.
3. Results
Of a total of 7121 pregnant women referred to
our clinic, 110 (1.58%) cases were detected with
a liver disease with an age range of 16-49 yr
(31 ± 6 yr); of these 105 women were diagnosed
with pregnancy-specific liver diseases, including
HELLP syndrome (10.9%) preeclampsia (50.98%),
partial HELLP (0.9%), eclampsia (0.9%), acute
fatty liver (9.1%), and intra-hepatic cholestasis 25
(22.7%) and 5 women were diagnosed with non-
pregnancy-specific liver disease, including liver
transplantation (2.7%), and autoimmune hepatitis
(1.8%). The mean gestational age was 35 wk, and
premature birth was 64.5%. In the participants with
liver transplantation, the mean age of pregnant
women was 29 years and the mean gestational
age was 37 weeks. The mean neonatal weight
was 2,696 gr and the mean apgar score was 8.
Cesarean section was indicated for all cases due to
physicians’ requests. No maternal mortality, IUGR,
and premature neonates were detected among
participants studied. Table I shows the relationship
between the participants’ characteristics and
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neonatal mortality. The neonatal mortality was
detected in preterm neonates with gestational
age 27.6 (5.16) wk, but not in the neonates
with gestational age 35.6 (2.9) wk (Table I).
There was a statistical significant relationship
between neonatal prematurity (p = 0.013),
gestational age (p < 0.001), IUGR (p < 0.001),
placental pathology (p = 0.041), neonatal weight
(p = 0.001) with neonatal mortality in this study
(Table I).
Table I. The relationship between participant’s characteristics, gestational age, neonatal weight, Apgar score with neonatal
mortality
Variables Neonatal mortality Total P-value*
Yes No
History of autoimmune disease∗
Yes 1 (10) 4 (4) 5 (4.5)
No 9 (90) 96 (96) 105 (95.5)
0.385
Liver function test returning to normal after delivery∗
Yes 8 (80) 88 (88) 96 (87.3)
No 2 (20) 12 (12) 14 (12.7)
0.613
Neonatal prematurity∗
Yes 10 (100) 61 (61) 71 (64.5)
No 0 (0) 39 (39) 39 (35.5)
0.013
Intra-uterine growth restriction∗
Yes 10 (100) 5 (5) 15 (13.6)
No 0 (0) 95 (95) 95 (86.4)
< 0.001
Placental pathology∗
Normal 8 (80) 98 (98) 106 (96.4)
Abnormal 2 (20) 2 (2) 4 (3.6)
0.041
Presentation∗
Cephalic 7 (70) 90 (90) 97 (88.2)
Breech 3 (30) 10 (10) 13 (11.8)
0.095
Delivery method∗
NVD 0 (0) 19 (19) 19 (17.3)
Cesarean section 10 (100) 81 (81) 91 (82.7)
0.137
Gestational age∗∗ 193.4 ±36.124 249.11 ± 20.503 244.05 ± 27.357 <0.001
Neonatal weight∗∗ 1072.50 ± 672.28 2844.55 ± 642.37 2683.46 ± 808.26 <0.001
Apgar score∗∗ 5 ± 2.449 8.64 ± 0.659 8.31 ± 1.413 <0.001
Fisher exact test for qualitative & man whitney U Test for quantitative variables, ∗ Data presented as n (%), ∗∗ Data presented as
Mean ± SD
4. Discussion
In this study, we evaluated the pregnancy
outcomes in pregnant women with liver
disease. We found that in pregnant women
with autoimmune hepatitis, the main outcome was
a premature birth and no maternal mortality was
detected in these patients. In contrast with our
study findings, Orgul et al., showed two cases
of autoimmune hepatitis in which one maternal
mortality was occurred (16). Nowadays, the overall
perinatal mortality is decreased because of the
better understanding of physiologic changes
during the pregnancy, team working, and on-
time intervention. In agreement with previous
studies, the prevalence of the liver disease in
pregnant women in our study was 1.58% (4,
8).
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This study showed that the mean age of the
pregnant women with liver disease was 31 ± 6
yr. Similarly to our study, Tiwari et al. assessed a
young study population with aged range of 20 to
29 years.They believed that a variety of liver tests
is very important before pregnancy for this age
range, especially if there is a history of past medical
diseases, such as chronic hypertension, diabetes
mellitus, autoimmune hepatitis, and liver disease
(4). In our study, 25.5% of our participants had a
history of hypertension and 10.9% had previous
liver disease.
The relationship between the gestational age at
the time of delivery and neonatal prematurity, has
been studied in several studies (1-15). The mean
gestational age in our study was 244.05 ± 27.357
days, and the preterm birth was detected in
64.5% of women that is high and corresponds
with previous studies (1-6, 8-15). In the study of
Carballo et al., GA was 35 wk and 6 days with 10%
premature delivery. The low prevalence of adverse
fetal outcomes in their study could be related to the
low rate of prematurity (7). According to the results
of this study, we can estimate that the percentage
of premature births in mothers with liver disease
was obviously high and this needs the availability
of medical equipment (such as NICU) at accessible
sites of such patients. This study showed that the
most common diseases related to liver dysfunction
were preeclampsia/ eclampsia with a rate of 51.88%
and cholestasis of pregnancy with a rate 22.7%.
Likewise, Tiwari et al. found that preeclampsia and
cholestasis were the most common complications
related with liver diseases with a prevalence of
66.35% and 16.8%, respectively (4).
The present study showed that in the
participants with liver transplantation, the mean
maternal age was 29 years and the mean
gestational age was 37 wk. The mean neonatal
weight was 2,696 gr, and the mean Apgar score
was 8. Cesarean section in all these cases
was performed due to physicians’ request. This
finding is in contrast with the study by Costa and
colleagues in which preterm delivery was 12.5-50%
(17).
Accordingly, in overall, pregnancy outcomes in
pregnant women with liver transplants can be
considered satisfactory. Meanwhile, these results
coincided with the findings of previous studies (17-
19), which found that women with chronic liver
disease are benefiting from excellent results after
liver transplantation with proper healthcare. In line
with previous studies, this study showed that the
meanweight of the neonatewas 2683 gr (5-7, 9-10).
It is well documented that the neonatal prematurity
causes a lack of maturation of the neonate’s lung
and oxygenation to the body and brain, which may
cause neonatal brain retardation, the increased risk
of mortality, and the need for medical equipment
(such as NICU). Similarly to one study conducted by
Carballo et al. (7), our study results shows that the
mean neonatal Apgar score is 8.31 ± 1.41, which is
in the normal range.
Consistent with earlier studies (1, 5, 6, 17-19), in
our study, a large number of deliveries (82.7%) were
performed by cesarean section, which is a high
rate. On the contrary, Rook et al. reported different
results in this regard. In their study, 84% of women
were delivered through normal vaginal delivery (12).
Due to the adverse effects of cesarean section
on the mother and the baby, diagnosis, treatment,
and care of the liver can minimize this mode of
delivery. Our study showed that hepatic enzymes
were returned to normal after delivery in 87.3% of
cases within 2 wk.
The neonatal mortality in this study was 9.1%.
The rate of neonatal mortality in developing
countries such as India was reported as 29.17%
(4). We found no maternal mortality due to liver
diseases. Since the maternal mortality is of the
most important and crucial health indicator related
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to the pregnancy, this finding is considered
satisfactory and indicating that liver disease is
not a serious threat to the mother. We had no
cases of any type of viral hepatitis, in contrast to
the study by Krishnamoorthy et al. who reported
pregnant women with viral hepatitis and high
perinatal mortality (20). The main limitation of our
study was the small number of cases such as liver
transplantation.
5. Conclusion
This study demonstrated that the liver disease
in pregnancy is not a risk to the mother and
most mothers return to normal after giving birth
and can take care of their newborns. However,
timely diagnosis, intervention, and monitoring
of mother and fetus with the teamwork of
obstetricians, neonatologists, gastroenterologists
and anesthetists can prevent and reduce
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